Early DOlutegravir/LAmivudine Switching After Virological Suppression (EDOLAS Study)

  • End date
    Apr 1, 2024
  • participants needed
  • sponsor
    Societa' Italiana Di Malattie Infettive E Tropicali
Updated on 5 August 2021


Phase III, randomized, open-label, multicentre, active-controlled, non-inferiority study evaluating the efficacy and safety of early switching to dolutegravir/lamivudine (DTG/3TC) in single-pill, in HIV-1 infected individuals currently taking an INSTI-based three-drug first-line regimen for less than 18 months and who have been virologically suppressed with HIV-1 RNA <50 copies/mL


The target population of this study is HIV-1-infected adults without previous virological failure, currently receiving any first-line, triple-drug ART having an INSTI (EVG/cobi, RAL QD, DTG, BIC) as anchor drug associated to any of the following dual NRTI backbone (ABC/3TC, TDF/FTC or TAF/FTC) with virological suppression (HIV-1 RNA < 50 copies/mL).

Participants will be randomly allocated 1:1 to switch to DTG/3TC 50/300 mg as a single pill qd until week 96 (Arm A, early switch) or to continue their INSTI-based ART triple regimen received at screening (Arm B, delayed switch) until week 52, when participants in Arm B with HIV-1 RNA< 50 cp/mL at week 48 will switch to DTG/3TC 50/300 mg qd as a single pill until week 100.

The drugs of both arms will be administered in an open-label manner throughout the entire duration of the study.

The primary analysis will take place after the last participant completes 52 weeks on therapy, to allow for the collection of a confirmatory viral load measurement in participants possibly presenting with HIV-1 RNA 50 cp/mL at the Week 48 visit.

If the second determination of HIV-1 RNA is <50 cp/mL, then the participant has not a virological rebound and will be considered eligible to switch to DTG/3TC at Week 52.

If the second determination of HIV-1 RNA is 50 cp/mL, then the participant will be considered protocol-defined virological failure, thus being ineligible to switch to DTG/ 3TC. These participants will be withdrawn from the study.

A preliminary interim analysis will be performed after 50% of the enrolled participants have reached the 24th week of study, always considering 4 weeks more (thus 28 weeks) to allow for the collection of a confirmatory viral load measurement in participants possibly presenting with HIV-1 RNA 50 copies/mL at Week 24.

At week 48, participants in Arm A (early switch) will continue DTG/3TC. At week 52, participants in Arm B (delayed switch) and with HIV-1 RNA < 50 copies/mL at week 48 will switch to DTG/3TC and will be followed until week 100.

The exploratory analyses at Week 96 will take place after the last participant completes 100 weeks on therapy, as needed, to allow for the collection of a confirmatory viral load measurement in participants presenting with HIV-1 RNA 50 copies/mL at Week 96.

Condition HIV-1-infection
Treatment DOVATO
Clinical Study IdentifierNCT04979468
SponsorSocieta' Italiana Di Malattie Infettive E Tropicali
Last Modified on5 August 2021


Yes No Not Sure

Inclusion Criteria

HIV-1 documented infection
Aged 18 years or older at the time of signing the informed consent
Stable INSTI-based first-line three-drug ART (switch between different NRTIs are allowed; e.g. from TDF/FTC to TAF/FTC or ABC/3TC, from TAF/FTC to TDF/FTC or ABC/3TC, from ABC/3TC to TAF/FTC or TDF/FTC). Any change of INSTI will not be allowed. Only the following regimens will be allowed
RAL 1200 mg QD plus TDF/FTC or TAF/FTC
RAL 1200 mg QD plus ABC/3TC
Previous INSTI-based first-line ART lasting less than 18 months before screening
To have reached a HIV-1 RNA <50 copies/mL during INSTI first-line therapy for less than 12 months. At least a single HIV-1 RNA determination below the threshold within the 6 months before enrollment is required (if a following determination in present, this should not be 50 copies (cp)/mL)
HIV-1 RNA below 50 copies/mL at the screening visit
No known allergy or intolerance to the study drugs or their components or drugs of their class
A female person is eligible to enter the study if it is confirmed that she is
Not pregnant confirmed by a negative serum pregnancy test at both Screening and Day1
Not breastfeeding
Of non-childbearing potential defined as either post-menopausal (12 months of spontaneous amenorrhea and 45 years of age) or physically incapable of becoming pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy
Of childbearing potential and agrees to utilize the protocol specified method of contraception (as defined in Appendix 1 -Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential) or be non-heterosexually active or practice sexual abstinence (defined as complete abstinence from penile-vaginal intercourse; periodic abstinence, e.g. calendar, ovulation, symptothermal, post-ovulation methods and withdrawal are not acceptable methods of contraception) from screening throughout the duration of study treatment and for at least two weeks following discontinuation of study drugs
Being able to comply with the protocol requirements and restrictions
Signature of written Informed Consent Form (participants or legal guardian) before that any protocol-specified assessments are conducted

Exclusion Criteria

A person will be considered not eligible for inclusion in this study if any of
the following criteria apply
Having failed virologically
Having changed the INSTI drug
Any major INSTI- or NRTI-resistance-associated mutation documented before starting ART
Women who are pregnant or breastfeeding or plan to become pregnant or breastfeed during the study
Evidence of Hepatitis B virus (HBV) infection based on the results of testing at screening for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-Hbc), hepatitis B surface antigen antibody (anti-HBs) and, possibly, HBV DNA as
Individuals positive for HBsAg are excluded
Individuals negative for anti-HBs but positive for anti-HBc (negative HBsAg status) and positive for HBV DNA are excluded
HCV-RNA positivity needing for any hepatitis C virus (HCV) therapy during the study
Ongoing malignancy other than cutaneous Kaposi's sarcoma (not requiring systemic therapy), basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical, anal or penile intraepithelial neoplasia
Active opportunistic infections requiring active treatment
Creatinine clearance of <50 mL/min/1.73m2 via CKD-EPI method
Individuals with severe hepatic impairment (Child Pugh class C) and/or unstable liver disease
Any verified Grade 4 laboratory abnormality at screening assessment
Alanine aminotransferase (ALT) >5 times the upper limit of normal (ULN) or ALT >3xULN and bilirubin >1.5xULN (with >35% direct bilirubin) at screening assessment
Receipt of investigational research agents within 30 days prior to study entry
Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of screening
Receipt of immunosuppressive medications or immune-modulators within the past 6 months
Individuals who in the investigator's judgment, poses a significant suicidality risk or with diagnosed major depression, Bipolar Disorders and Psychoses
A life expectancy estimated as less than 2 years
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note